4D Molecular Therapeutics, Inc. (FDMT)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
David H. Kirn
Employees:
120
5858 HORTON STREET #455, EMERYVILLE, CA 94608
5105052680

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa, choroideremia, and 4 D-310.

Data derived from most recent annual or quarterly report
Market Cap 610.847 Million Shares Outstanding33.234 Million Avg 30-day Volume 625.119 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.79
Price to Revenue254.7634 Debt to Equity0.0 EBITDA-109.162 Million
Price to Book Value2.5732 Operating Margin-5151.5399 Enterprise Value360.658 Million
Current Ratio18.358 EPS Growth-0.216 Quick Ratio17.774
1 Yr BETA 1.2107 52-week High/Low 26.49 / 5.32 Profit Margin-4974.5471
Operating Cash Flow Growth-17.7579 Altman Z-Score10.7445 Free Cash Flow to Firm -70.046 Million
Earnings Report2023-08-10
View SEC Filings from FDMT instead.

View recent insider trading info

4D Molecular Therapeutics, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding FDMT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FDMT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-25 by MILLER-RICH NANCY
  • 4: filed on 2023-05-25 by GRAY SUSANNAH
  • 4: filed on 2023-05-25 by KASAHARA NORIYUKI
  • 4: filed on 2023-05-16 by MORETTI AUGUST J
  • 4: filed on 2023-05-11 by VIKING GLOBAL INVESTORS LP
  • 4: filed on 2023-05-04 by KIRN DAVID
  • 4: filed on 2023-04-25 by BIZILY SCOTT
  • 4: filed on 2023-04-25 by CHACKO JACOB
  • 4: filed on 2023-03-03 by BIZILY SCOTT
  • 4: filed on 2023-02-23 by KIRN DAVID

    • Events (8k)

  • 8-K: filed on 2023-05-25:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-03:
    Item 8.01: Other Events
  • 8-K: filed on 2023-01-26:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-21:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-04-21:
  • 144: filed on 2023-04-21:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    850 Thousand total shares from 1 transactions

    Open Market Sells (S)

    8.8 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    11.8 Thousand total shares from 3 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MILLIGAN JOHN F

    • Director
    		 0 2023-05-23 1

    CHACKO JACOB

    • Director
    		 0 2023-05-23 2

    TOMASELLO SHAWN

    • Director
    		 0 2023-05-23 1

    THEUER CHARLES

    • Director
    		 0 2023-05-23 1

    MILLER-RICH NANCY

    • Director
    		 0 2023-05-23 1

    GRAY SUSANNAH

    • Director
    		 0 2023-05-23 1

    KASAHARA NORIYUKI

    • Director
    		 0 2023-05-23 3

    MORETTI AUGUST J CHIEF FINANCIAL OFFICER

    • Officer
    		 11,045 2023-05-15 4

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    VIKING GLOBAL OPPORTUNITIES PARENT GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    		 4,787,914 2023-05-09 1

    KIRN DAVID CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,859,153 2023-05-02 5

    BIZILY SCOTT CHIEF LEGAL AND HR OFFICER

    • Officer
    		 2,109 2023-04-21 6

    KIM ROBERT YOUNG CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-03-24 1

    KAMAL FARIBORZ PRESIDENT & COO

    • Officer
    		 0 2023-02-10 3

    FISHMAN ROBERT S CHIEF MEDICAL OFFICER

    • Officer
    		 60,000 2022-09-01 1

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		3,912,984 2022-06-16 1

    ZIMMERMANN CAROLYNE CHIEF BUSINESS OFFICER

    • Officer
    		 35,000 2022-02-01 0

    SCHAFFER DAVID

    • Director
    		 901,215 2021-10-20 0

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    		 3,937,914 2020-12-15 0

    YAO TONY DUNG LING

    • Director
    		 1,063,744 2020-12-15 0

    BURKOTH WILLIAM T.

    • Director
    		 0 2020-12-10 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    MILLIGAN JOHN F - Director

    		2023-05-25 19:42:12 -0400 2023-05-23 A 33,750 a 33,750 direct

    TOMASELLO SHAWN - Director

    		2023-05-25 19:39:14 -0400 2023-05-23 A 22,500 a 22,500 direct

    MILLER-RICH NANCY - Director

    		2023-05-25 19:37:06 -0400 2023-05-23 A 22,500 a 22,500 direct

    THEUER CHARLES - Director

    		2023-05-25 19:35:36 -0400 2023-05-23 A 22,500 a 22,500 direct

    GRAY SUSANNAH - Director

    		2023-05-25 19:33:54 -0400 2023-05-23 A 22,500 a 22,500 direct

    CHACKO JACOB - Director

    		2023-05-25 19:32:17 -0400 2023-05-23 A 22,500 a 22,500 direct

    KASAHARA NORIYUKI - Director

    		2023-05-25 19:31:19 -0400 2023-05-23 A 22,500 a 22,500 direct

    MORETTI AUGUST J - Officer CHIEF FINANCIAL OFFICER

    		2023-05-16 20:52:00 -0400 2023-05-15 M 3,000 $9.41 a 11,045 direct -3.0253 -0.7151 0.8251 4 -3.0253 2

    MORETTI AUGUST J - Officer CHIEF FINANCIAL OFFICER

    		2023-05-16 20:52:00 -0400 2023-05-15 M 3,000 d 217,060 direct

    VIKING GLOBAL INVESTORS LP - > 10% Owner see explanation responses

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP - > 10% Owner see explanation responses

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC - > 10% Owner see explanation responses

    VIKING GLOBAL OPPORTUNITIES GP LLC - > 10% Owner see explanation responses

    VIKING GLOBAL OPPORTUNITIES PARENT GP LLC - > 10% Owner see explanation responses

    HALVORSEN OLE ANDREAS - > 10% Owner see explanation responses

    OTT DAVID C. - > 10% Owner see explanation responses

    SHABET ROSE SHARON - > 10% Owner see explanation responses

    		2023-05-11 17:50:40 -0400 2023-05-09 P 850,000 $16.00 a 4,787,914 indirect -0.5025 0.7817 1.5075 4 -1.5634 5

    KIRN DAVID - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-05-04 20:09:22 -0400 2023-05-02 G 600,000 d 1,259,153 direct -2.4793 5.7261 5.7261 6 -2.4793 2

    KIRN DAVID - Director - Officer CHIEF EXECUTIVE OFFICER family trusts

    		2023-05-04 20:09:22 -0400 2023-05-02 G 600,000 a 600,000 indirect -2.4793 5.7261 5.7261 6 -2.4793 2

    CHACKO JACOB - Director

    		2023-04-25 18:43:09 -0400 2023-04-21 M 5,000 $9.41 a 5,000 direct yes -19.7861 -7.5352 0.0 1 -19.7861 2

    BIZILY SCOTT - Officer CHIEF LEGAL AND HR OFFICER

    		2023-04-25 18:44:59 -0400 2023-04-21 M 3,750 d 52,500 direct yes

    BIZILY SCOTT - Officer CHIEF LEGAL AND HR OFFICER

    		2023-04-25 18:44:59 -0400 2023-04-21 S 3,750 $20.00 d 2,109 direct yes -19.7861 -7.5352 0.0 1 -19.7861 2

    BIZILY SCOTT - Officer CHIEF LEGAL AND HR OFFICER

    		2023-04-25 18:44:59 -0400 2023-04-21 M 3,750 $8.04 a 5,859 direct yes -19.7861 -7.5352 0.0 1 -19.7861 2

    CHACKO JACOB - Director

    		2023-04-25 18:43:09 -0400 2023-04-21 M 5,000 d 32,500 direct yes

    CHACKO JACOB - Director

    		2023-04-25 18:43:09 -0400 2023-04-21 S 5,000 $20.05 d 0 direct yes -19.7861 -7.5352 0.0 1 -19.7861 2

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 22:15:04 UTC 4.6194 0.4406 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 21:45:04 UTC 4.6194 0.4406 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 21:15:03 UTC 4.6194 0.4406 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 20:45:04 UTC 4.6194 0.4406 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 20:15:06 UTC 4.6194 0.4406 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 19:45:04 UTC 4.6194 0.4406 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 19:15:21 UTC 4.5869 0.4731 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 18:45:03 UTC 4.5869 0.4731 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 18:15:04 UTC 4.5869 0.4731 400000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 17:45:03 UTC 4.5869 0.4731 400000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 17:15:05 UTC 4.5869 0.4731 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 16:45:04 UTC 4.8008 0.2692 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 16:15:04 UTC 4.8008 0.2692 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 15:45:03 UTC 4.8008 0.2692 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 15:15:04 UTC 4.8008 0.2692 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 14:45:04 UTC 4.8008 0.2692 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 14:15:03 UTC 4.8008 0.2692 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 13:45:04 UTC 4.8092 0.2608 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 13:15:04 UTC 4.8092 0.2608 500000
    4D MOLECULAR THERAPEUTICS IN FDMT 2023-05-31 12:45:04 UTC 4.8092 0.2608 500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments